Poly-unsaturated Fats for Improving Nasal Polyps and Asthma
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Asthma is a syndrome compromising many phenotypes including N-ERD (caused by increased
4-series leukotriene (LT) production). n-3 PUFA supplementation modulates 4-series LT and has
anti-inflammatory effects. However, other than in a pilot study with dietary manipulation,
the effects of N-ERD are unknown. The primary objective is to determine whether n-3 PUFA
supplementation in people with N-ERD can improve asthma control using the asthma control
questionnaire (ACQ-7). This is a placebo controlled randomised controlled parallel
multicentre study with of 6g per day of PUFA for 6 months in people with N-ERD and poor
asthma control
Phase:
Phase 3
Details
Lead Sponsor:
Norfolk and Norwich University Hospitals NHS Foundation Trust